Menarini Ricerche

• European Commission

  HORIZON-JU-RIA, Cities@Heart: City-based Strategies for improving Cardiovascular Health in Europe, 101219389, 2026–2030, 17 Dec 2025

• European Commission

  HORIZON-JU-RIA, Collaborative Action and Research for Engagement, Persistence and Adherence in Treatment & Health, 101192133, 2025–2030, 8 May 2025

Sources: cordis.europa.eu

• Cardiovascular Risk in SELECT-Eligible MI Patients With Overweight or Obesity: The Western Denmark Heart Registry

  Consulting or advice, Fees or honoraria, 9 Oct 2026

• Multiorgan protective therapy for CKM syndrome: the role of GLP-1-based therapies and SGLT2 inhibitors

  Consulting or advice, Fees or honoraria, 24 Sept 2026

• From adiposity to multisystem morbidity: the case for weight loss as disease modification

  Consulting or advice, Fees or honoraria, 27 Aug 2026

• Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome

  Consulting or advice, Fees or honoraria, 19 Aug 2026

• Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials

  Consulting or advice, Fees or honoraria, 13 Aug 2026

• Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF)

  Consulting or advice, Fees or honoraria, 11 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov, europepmc.org